Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

Zeuzem, Stefan; Mantry, Parvez S.; Soriano, Vincent; Buynak, Robert; Dufour, Jean–François; Pockros, Paul J.; Wright, David W.; Angus, Peter W; Buti, María; Stern, Jerry O.; Kadus, Werner; Vinisko, Richard; Böcher, Wulf O.; Mensa, Federico

doi:10.1097/meg.0000000000000649

Cited by 1 publication

(1 citation statement)

References 6 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients were treated with SOF/RBV + Peg-INF regimen and it was reported that SVR rate was 99% in subjects with CC genotype and 87% in subjects with non-CC genotypes [ 4 ]. Also, in patients with IL28B non-CC genotype and infected with HCV-1a, Peg-INF-free regimens included combination of deleobuvir, faldaprevir, and ribavirin resulted in low SVR rates [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Attallah

Omran

Abdelrazek

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Impact of interleukin 28B (IL28B) rs12979860 polymorphism on response to direct-acting antivirals agents in HCV genotype 4-infected patients is under investigation. Zinc may have an advantage in improvement of liver damage and treatment outcome. We aimed to evaluate IL28B polymorphism and zinc administration impact on patient response to treatment and amelioration of liver fibrosis. Results Three hundred patients on anti-HCV treatments were equally categorized into patients treated with dual therapy (sofosbuvir/ribavirin) for 24 weeks, triple therapy (sofosbuvir/ribavirin+pegylated interferon-alpha) for 12 weeks, dual therapy plus oral zinc and with triple therapy plus oral zinc. All patients were genotyped for IL28B. Sustained virologic response (SVR) was achieved in 100% of patients with CC genotypes while 15.5% of CT/TT carriers did not attain SVR. After treatment, patients with CC genotype showed improvement in liver-related parameters compared with CT/TT genotypes. Zinc supplementation was associated with improved SVR in CT/TT genotypes and liver parameters in both CC and CT/TT genotypes. Hepatic fibrosis was improved in higher percent of CC genotype (16.7%) compared with CT/TT genotypes (5.8%). Interestingly with zinc administration, improved fibrosis increased to 60.9% in CC genotype vs. 15.4% in CT/TT genotypes. Conclusion Absolute SVR rates in patients with IL28B CC genotype support their selection for shorter treatment duration and therefore associated with high economic value. IL28B polymorphism is associated with improvement of hepatic functions and fibrosis after antiviral treatments. Zinc is powerful supplement not only to increase SVR in non-responders but also to improve hepatic functions and fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Attallah

Omran

Abdelrazek

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

show abstract

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study

Abstract: In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313).

Cited by 1 publication

References 6 publications

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Contact Info

Product

Resources

About